Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zimmer Keeps Women Waiting For Gender-Specific Knee; Q3 Sales Growth Suffers

This article was originally published in The Gray Sheet

Executive Summary

Zimmer's inability to meet demand for its Gender Solutions high-flex knee replacement due to constrained manufacturing capacity was among factors limiting the firm's third-quarter knee sales growth to 8%, according to the company

You may also be interested in...



Zimmer’s Female-Specific Knee Beats High Expectations In Fourth Quarter

Implants of over 9,500 Zimmer Gender Solutions knee replacement systems in the fourth quarter of 2006 helped drive the firm's worldwide knee revenue ahead 11%, year-over-year, to $389 million

Zimmer’s Female-Specific Knee Beats High Expectations In Fourth Quarter

Implants of over 9,500 Zimmer Gender Solutions knee replacement systems in the fourth quarter of 2006 helped drive the firm's worldwide knee revenue ahead 11%, year-over-year, to $389 million

Knees for the ladies

Zimmer announces 510(k) clearance of its Gender Solutions high-flex knee replacement May 10. The knee, based upon the firm's NexGen technology, is tailored to fit women and small men by incorporating a narrower shape and unique angle by which the kneecap tracks over the femur. Zimmer estimates that two-thirds of knee replacements in the $4.6 bil. market are for women. The firm plans to spend $10 mil. a year in direct-to-consumer advertising for the product (1"The Gray Sheet" March 27, 2006, p. 10)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024144

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel